Last year, OncoMyx Therapeutics unveiled preclinical data showing its engineered rabbit pox virus therapy could slow tumor growth in mouse models of melanoma and bone cancer. Now, it's unveiling more preclinical evidence, this time in non-small cell lung cancer (NSCLC).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,